ZOTANSE23 November 2019

Zota Health Care LImited has informed the Exchange regarding Investor Presentation

Zota Health Care LImited

A zoto'

healthcare Itd.

November 23,2019

To, The Manager Listing Department, The National Stock Exchange of lndia Limited Exchange Plaza,

Bandra Kurla CompJex, Bandra (E), Mumbai - 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Investor Presentation

Ref: Regulation 30(6) of SEB| (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited (the "Company") are submitting herewith enclosed the lnvestor Presentation, November, 2019.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

Encl: a/a

(

L

t

Registered Qffiee: Zoto House, 2/896,Hiro Modi Street Sogrompuro, Surot - 395 OO2 | Ph: +91 261 23316,C.1 Emcil: info@zotoheolthcqre.com Web : wrrvw.zotohec lthccre.com

Plsnt: Plot no. 169 Surot Specicl Economic Zone!, Nr. Sochin Roilwoy Stotioq, Sochin, Surqt - 394 23O (Guj.) Indio Ph: +9.1 261 2397122 ..'

i'

j

\-

CIN : L2423.]GJ2OOOPLCO3B352

v \,/

\

""'-"--'/'

/

\\

ta

,-1--

-.-

H1FY20 P E R F O R M A N C E H I G H L I G H T S

N O V E M B E R 2 0 1 9

S A F E H A R B O R

This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer documents.

This presentation has been prepared on the basis of information and data available with the Company consider reliable. This presentation may not contain all the information that you may consider material. Any liability in respect of the content of or any omission from this presentation is expressly excluded. Stakeholders are advice to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on website of NSE.

This presentation contains “forward looking statement”, including “future oriented financial information” and “financial outlook”. This forward looking statement is based on management’s current expectations and belief, and subject to uncertainty. Actual result may be vary from the material facts contained in this presentation due to changes in government policies, regulations, economics reforms, natural calamities, competition, technology, etc. Company is not under obligation to inform any update or alter in forward looking statement, whether as a result of any new information or future events

2

T A B L E O F C O N T E N T S

Result Highlights

Operational Metrics

Davaindia

Business Outlook & Strategy

Financial Summary

4

9

12

21

23

3

Result Highlights

Q u a r t e r l y F I N A N C I A L H I G H L I G H T S

Revenues (INR Lakhs)

Gross Profit (INR Lakhs)

Gross Profit (%)

PAT (INR Lakhs)

4.4%

-10.4%

-480 bps

-55.4%

2528.7

2422.3

819.5

33.8

733.9

245.9

29.0

109.6

Q2FY19

Q2FY20

Q2FY19

Q2FY20

Q2FY19

Q2FY20

Q2FY19

Q2FY20

5

H A L F Y E A R L Y F I N A N C I A L H I G H L I G H T S

Revenues (INR Lakhs)

Gross Profit (INR Lakhs)

8.6%

-6.3%

Gross Profit (%)

-473 bps

PAT (INR Lakhs)

-59.9%

4,696. 9

4,326. 6

1,497.0 2

1,402.6 1

34.60

412.4

29.86

165.3

H1FY19

H1FY20

H1FY19

H1FY20

H1FY19

H1FY20

H1FY19

H1FY20

6

P R O F I T & L O S S S T A T E M E N T - Q u a r t e r l y

Particulars (Rs Lakhs) Export Sales (SEZ) Dava India Sales Domestic Sales Revenues from Operations Cost of Goods Sold

Gross Profit % Margin Operational Exp Employee cost Other expenses

Operating Profit % Margin Other Income EBITDA % Margin Depreciation EBIT

% Margin Interest Cost EBT % Margin Taxes Profit After Taxes % Margin

Q2FY20 342.0

307.0

1,879.7

2,528.7 1,794.8 733.9 29.0 591.9 259.0 332.9 142.0 5.6 37.5 179.5 7.1 32.0 147.4

5.8

1.0 146.4 5.8 36.8 109.6 4.3

Q2FY19 532.1

143.0

1,747.2

2,422.3 1,602.8 819.5 33.8 483.8 226.7 257.1 335.7 13.9 62.2 397.9 16.4 35.2 362.7

15.0

0.2 362.4 15.0 116.6 245.9 10.2

YoY % -35.7

114.7

7.6

4.4 12.0 -10.4

22.3

QoQ % -25.9

33.2

27.4

16.6 19.7 9.8

1.5

-57.7

66.4

-54.9

-8.9 -59.4

328.4 -59.6

-68.4 -55.4

55.9

6.7 73.3

-21.4 74.7

33.3 95.1

Q1FY20 461.8

230.4

1,475.9

2,168.2 1,499.5 668.7 30.8 583.4 243.5 339.9 85.3 3.9 29.8 115.1 5.3 30.0 85.1

3.9

1.3 83.8 3.9 27.6 56.2 2.6

7

M A N A G E M E N T C O M M E N T A R Y

Revenues for the Q2FY20 increased by 4.4% YoY & 16.6%QoQ backed by sales growth in the domestic operations 7.6%/27.36 YoY/QoQ and DavaIndia sales growth of 114.7%/33.2% YoY/QoQ

• Gross Profit margins for the quarter declined 481 bps YoY on account of higher material cost and lower export sales.

EBITDA margins at 7.1% YoY to Rs 147.4 lakhs a dip due to higher operational expenses and accordingly PAT dipped and stood at Rs. 109.6 Lakhs

8

Operational Metrics

O P E R A T I O N A L M E T R I C S - D O M E S T I C

Revenues (INR Lakhs)

9.0%

3,624.9

3,950.6

EBITDA (INR Lakhs)

-67.4%

PAT (INR Lakhs)

-67.8%

564.9

311.3

184.4

100.2

H1FY19

H1FY20

H1FY19

H1FY20

H1FY19

H1FY20

Note: Revenues includes other income

10

O P E R A T I O N A L M E T R I C S - E X P O R T S

Revenues (INR Lakhs)

1.5%

EBITDA (INR Lakhs)

-7.9%

119.7

PAT (INR Lakhs)

-35.8%

801.9

813.6

110.2

101.3

65.0

H1FY19

H1FY20

H1FY19

H1FY20

H1FY19

H1FY20

Note: Revenues includes other income

11

The retail pharmacy stores continues its stellar performance in terms of its expansion and total customers serviced, as awareness towards generic drugs usage keeping gaining traction

Being asset light in nature the store continues to remain focused on chronic ailments – Cardiac, Diabetic, Thyroid and Neuropsychiatric ailments as repeat business from customer guides for store revenue visibility

DavaIndia store expansion have doubled at 202 stores as on date with higher number of stock keeping units per store

Higher number of SKU’s stood at 1,340 resulting in servicing more number of customers at the store point. As on date, DavaIndia reached a remarkable feat of catering to 1.2mn customers in a short span of time, reflecting fruition of the management vision and efforts

DavaIndia is India’s only retail generic pharmacy in which 95% products are private label products (i.e. DavaIndia’s own brand).It has 76 store openings signed up thus underlying its expansion strategy

13

14

P R E - O P E N I N G S T O R E A C T I V I T I E S F O R D A V A I N D I A

PAMPHLET DISTRIBUTION

BULK SMS TO RESIDENTS IN AND AROUND THE VICINITY

SOCIAL MEDIA INITIATIVES

15

C O S T I N C U R R E D F O R D A V A I N D I A S T O R E O P E N I N G

Initial cost (₹) - 3,60,000-4,00,000

Operating Cost (₹) - 40,000 p.m.

Cardiac

Diabetic

Thyroid ailments

RENT

PHARMACIST MANPOWER

₹15,000 – ₹20,000

₹15,000

OTHER MISCELLANEOUS EXPENSES

₹5,000

Dermo

INVENTORIES - MEDICINES

₹1,50,000-2,00,000

Initial Cost Includes Inventories

16

O P E R A T I N G M O D E L O F D A V A I N D I A

Promotions & Brand building by ZHCL

Hoardings, Newspaper Advertisements & much more

95% Private Label Brands

Key brands – DavaIndia, Nutravedic, etc.

Cloud based software, mobile app, AI base-tools

Real-time data recording & supply management

Product portfolio of 1,340+ SKU’s

Focused on Cardiac , Diabetic, Thyroid ailments

202+ Stores

Retail Generic Pharmacy Chain

100% Franchise Models

Asset-light model, stores owned & operated by franchise

Exclusive sale of DavaIndia products

70% Medicine / 30% OTC products

17

D A V A I N D I A S T O R E S R O L L O U T

Store roll-out

28

29

29

39

33

27

15

2

144

Average Wallet Spend

202

Stores Opened

12 lakh

Customers Served

H2FY18

Q1FY19

Q2FY19

Q3FY19

Q4FY19

Q1FY20

Q2FY20

1st Oct - 15th Nov, 2019

4,250 lakh

Saved by our customers

18

D A V A I N D I A F O O T P R I N T S

HARYANA (4)

RAJASTHAN (3) Jaipur, Jodhpur, Sikat

GUJARAT (96)

Surat, Navsari, Kheda, Vadodara, Rajkot, Ahmedabad, Gandhinagar, Mehsana, Sabarkantha, Banaskantha, Vapi, Bharuch, Bilimora, Godhra, Valsad, Himmatnagar Kutch

MAHARASHTRA (45)

Nagpur, Pune, Chikhli, Mumbai, Latur, Nasik, Aurangabad, Solapur, Amravati

NEW DELHI (1)

UTTARAKHAND (2)

Dehradun

UTTAR PRADESH (9) Firozabad, Ghaziabad, Lucknow, Varanasi, Jhansi, Amhora

% Davaindia across states

2 1 1 1 1

4

MADHYA PRADESH (40) Indore, Jabalpur, Bhopal, Sagar, Guna, Dhar, Gwalior, Khandwa, Mandsaur, Itarsi, Rewa Harda

20

48

Gujarat

Maharashtra

Madhya Pradesh

Uttar Pradesh

Haryana

Rajasthan

Kerala

Uttrakhand

New Delhi

19

KERALA (2)

22

Sales trend of matured stores

12+ Months

3.52 lakhs

9 – 11 Months

1.90 lakhs

7 – 9 Months

1.60 lakhs

Top 10 stores

11th to 20th store

21st to 30th store

Average month sales of the stores

Average age of stores

The company also has vision to expand its chain to 3000 stores by the end of FY2022E

20

Business Outlook & Strategy

B U S I N E S S P E R F O R M A N C E O U T L O O K

• Domestic business will grow at constant rate of 12%-15% in FY20E, which will be a similar growth rate as previous

year

Export revenues being a higher margin business are expected to grow at a faster rate of 30%-40% in FY20E, as your company has expanded its global footprints in new geographies

• After successfully launching Dava India we have begun to execute the store expansion plans on a PAN India basis.

22

Financial Summary

P R O F I T & L O S S S T A T E M E N T - A N N U A L L Y

Particulars (INR Lakhs)

FY14

FY15

FY16

FY17

FY18

FY19

H1FY18

H1FY19

H1FY20

Income from Operations

5,011.2

5,646.3

6,473.3

7,158.0

7,785.2

8,562.9

3,913.7

4,326.6

4,696.9

10.2

1.4

7.7

5.6

151.9

154.5

60.5

100.3

67.3

Other Income

Total Income

Operating Expenses

4,362.0

4,796.5

5,516.8

6,153.8

6,695.0

5,021.4

5,647.8

6,481.0

7,163.6

7,937.0

8,717.4

7,788.4

3,974.1

4,426.8

3,311.8

3,742.2

EBITDA

Margin %

Depreciation

EBIT

Margin %

Financial Charges

PBT

Margin %

Tax

PAT

Margin %

EPS

659.4

13.2

120.7

538.7

10.7

71.4

467.3

9.3

156.0

311.3

6.2

2.6

851.3

15.1

150.6

700.7

12.4

66.5

634.2

11.2

207.6

426.7

7.6

3.0

964.2

14.9

123.5

840.8

13.0

68.3

772.4

11.9

261.5

510.9

7.9

3.6

1,009.8

1,242.0

14.1

105.4

904.4

12.6

68.2

836.2

11.7

282.1

554.1

7.7

3.9

16.0

93.7

1,148.3

14.8

12.1

1,136.2

14.6

407.4

726.8

9.3

4.2

929.0

10.8

139.4

789.6

9.2

3.7

785.9

9.2

230.7

555.2

6.5

3.2

662.4

684.6

16.7

46.3

15.5

75.9

616.1

608.6

15.5

9.2

606.9

15.3

204.6

402.4

10.1

2.3

13.7

0.7

607.9

13.7

195.5

412.4

9.3

2.4

4,764.2

4,469.6

294.6

6.2

62.1

232.5

4.9

2.3

230.2

4.8

64.9

165.3

3.5

0.7

24

B A L A N C E S H E E T & K E Y R A T I O S

Particulars (INR Lakhs)

Share capital

Reserves and Surplus

Non-current liabilities

Current liabilities

Total Equity and Liabilities

Non-current assets

Current assets

Total Assets

Key Ratios

RoCE (%)

RoE (%)

Net debt to equity (x)

Interest coverage (x)

Inventory days

Receivables days

Payable days

FY14

1,196.9

384.2

521.3

1,381.7

3,484.1

926.3

2,557.8

3,484.1

FY14

17.4

19.7

0.3

7.5

91.2

77.8

109.0

FY15

1,436.3

395.7

548.7

1,657.6

4,038.4

842.4

3,196.0

4,038.4

FY15

20.0

23.3

0.3

10.5

113.9

75.6

116.2

FY16

1,436.3

707.8

272.7

1,988.3

4,405.2

855.6

3,549.5

4,405.2

FY16

23.5

23.8

0.1

12.3

92.1

89.0

126.5

FY17

1,436.3

1,262.0

466.8

2,215.4

5,380.5

932.5

4,447.9

5,380.5

FY17

19.3

20.5

0.1

13.3

121.9

87.1

148.4

FY18

1,754.3

5,223.4

64.7

2,137.0

9,179.4

3,605.4

5,574.1

9,179.4

FY18

10.5

10.4

0.0

94.8

113.8

107.5

117.8

FY19

1,754.3

5,138.5

87.1

1,981.6

8,961.5

2,724.1

6,237.4

8,961.5

H1FY20

2,456.0

4,318.1

94.5

2,368.5

9,237.1

2,670.2

6,566.9

9,237.1

FY19

H1FY20

8.1

8.1

0.0

214.5

138.6

94.2

103.5

2.5

2.4

0.0

101.1

110.8

103.4

100.4

25

C O N T A C T I N F O R M A T I O N

Thank You

Mr. Himanshu Zota / Mr. Ashvin Variya

"ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002(Gujarat)

cszota@zotahealthcare.com

cszota@zotahealthcare.com

www.zotahealthcare.com

← All TranscriptsZOTA Stock Page →